Peptide dosing chart
Most dosing charts list compounds against numbers. This one does something more useful first: it tells you what kind of dose information exists at all for each of the 110 peptides, because that determines how much weight any number deserves.
A figure from an approved label and a figure circulating on a forum are not the same kind of fact, and a chart that prints them in the same column quietly says they are.
What this is The four dosing bands, applied to every entry
What it is not A list of doses to follow, or medical advice
Edition 1.0, regulatory status as at 16 September 2026
The four bands
Band 1, Approved dosing. A regulator has reviewed the evidence and approved a dose for a named indication. The label is the authority.
Band 2, Studied in trials. Doses used in published human trials, under supervision we cannot reproduce. Not approved dosing.
Band 3, Commonly reported. What circulates in community and clinic use, described and not recommended. No trial has established it.
Band 4, Insufficient data. No reliable human dosing information exists. In a few cases we also decline to repeat circulating figures where the harm profile makes that irresponsible.
The bands are published in full in how we rate evidence.
Band 1: Approved dosing (30 peptides)
| Peptide | Evidence | Safety data | United States | Australia |
|---|---|---|---|---|
| Abaloparatide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Calcitonin | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Desmopressin | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Dulaglutide | ★★★★★ | Well characterised | FDA approved (type 2 diabetes) | Schedule 4: ARTG-registered |
| Enfuvirtide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Exenatide | ★★★★☆ | Well characterised | FDA approved (type 2 diabetes) | Schedule 4 |
| Glucagon | ★★★★★ | Well characterised | FDA approved | Schedule 3: pharmacist only medicine |
| Gonadorelin | ★★★★☆ | Well characterised | Approved (some formulations) | Schedule 4 |
| hCG | ★★★★☆ | Well characterised | FDA approved | Schedule 4 (Prescription Only) |
| Icatibant | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Insulin | ★★★★★ | Well characterised | FDA approved | Schedule 4: ARTG-registered |
| Leuprolide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Linaclotide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Liraglutide | ★★★★★ | Well characterised | FDA approved | Schedule 4 (Prescription Only) |
| Melanotan I | ★★★★☆ | Moderately characterised | FDA approved (Scenesse, narrow indication) | Schedule 4; Scenesse ARTG-registered |
| Octreotide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Oral GLP-1 Peptides | ★★★★☆ | Well characterised | FDA approved (Rybelsus) | Schedule 4: ARTG-registered |
| Orforglipron | ★★★★☆ | Moderately characterised | FDA approved 1 April 2026 (Foundayo) for weight management | Not approved |
| Oxytocin | ★★★★☆ | Moderately characterised | FDA approved (obstetric) | Schedule 4: ARTG-registered (obstetric) |
| Plecanatide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Pramlintide | ★★★★☆ | Well characterised | FDA approved (adjunct in diabetes) | Schedule 4 |
| PT-141 | ★★★★☆ | Well characterised | FDA approved | Not named in the Poisons Standard |
| Semaglutide | ★★★★★ | Well characterised | FDA approved | Schedule 4 (Prescription Only) |
| Setmelanotide | ★★★★★ | Well characterised | FDA approved (rare genetic obesity) | Schedule 4: prescription only |
| Somatropin | ★★★★★ | Well characterised | FDA approved | Schedule 4 + Appendix D, clause 5 |
| Teduglutide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Teriparatide | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
| Tesamorelin | ★★★★☆ | Well characterised | FDA approved | Schedule 4; captured by Appendix D cl.5 class entry (GHRHs) |
| Tirzepatide | ★★★★★ | Well characterised | FDA approved | Schedule 4 (Prescription Only) |
| Vasopressin | ★★★★★ | Well characterised | FDA approved | Schedule 4: prescription only |
Band 2: Studied in trials (21 peptides)
| Peptide | Evidence | Safety data | United States | Australia |
|---|---|---|---|---|
| ARA-290 | ★★★☆☆ | Poorly characterised | Investigational | Not listed by name; unapproved therapeutic good |
| Argireline | ★★★☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Cagrilintide | ★★★☆☆ | Poorly characterised | Investigational | Not approved |
| CagriSema | ★★★☆☆ | Moderately characterised | Investigational | Not approved |
| Cerebrolysin | ★★★☆☆ | Moderately characterised | Not approved | Not registered; unapproved therapeutic good |
| Collagen Peptides | ★★★☆☆ | Well characterised | Dietary supplement: lawfully sold | Food / supplement: lawfully sold |
| Compounded GLP-1 Products | ★★★☆☆ | Poorly characterised | Compounding restricted | Pharmacist compounding prohibited |
| Davunetide | ★★★☆☆ | Moderately characterised | Investigational; phase 2/3 primary endpoints not met | Not approved |
| GHK-Cu | ★★☆☆☆ | well-characterised (topical) / poorly characterised (injected) | Topical cosmetic: lawful. Injectable: not approved | Topical cosmetic: lawful. Injectable: Schedule 4 |
| Kisspeptin-10 | ★★☆☆☆ | Poorly characterised | Investigational; current 503A Category 2 substance (29 September 2023) | Not listed by name; unapproved therapeutic good |
| Larazotide | ★★★☆☆ | Moderately characterised | Investigational | Not listed by name; unapproved therapeutic good |
| Matrixyl | ★★★☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Mazdutide | ★★☆☆☆ | Poorly characterised | Not approved | Not approved |
| NAD+ and Precursors | ★★★☆☆ | Moderately characterised | NMN status contested; NR lawful as a supplement | Supplement status varies; NMN restricted |
| Palmitoyl Tripeptide-1 | ★★★☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Retatrutide | ★★☆☆☆ | Poorly characterised | Investigational | Not listed by name; unapproved therapeutic good |
| Sermorelin | ★★★★☆ | Moderately characterised | Previously approved; now compounded | Schedule 4; captured by Appendix D cl.5 class entry (GHRHs) |
| SS-31 | ★★★☆☆ | Moderately characterised | Investigational | Not listed by name; unapproved therapeutic good |
| Survodutide | ★★☆☆☆ | Poorly characterised | Investigational | Not approved |
| Tesofensine | ★★★☆☆ | Poorly characterised | Not approved | Not approved |
| Thymosin Alpha-1 | ★★★★☆ | Moderately characterised | Not approved | Not ARTG-registered |
Band 3: Commonly reported (20 peptides)
| Peptide | Evidence | Safety data | United States | Australia |
|---|---|---|---|---|
| AHK-Cu | ★★☆☆☆ | Poorly characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| AOD-9604 | ★★☆☆☆ | Moderately characterised | Not approved; removed from Cat 2 Sep 2024 | Appendix D cl.5: possession without authority illegal (named with CAS No. 221231-10-3) |
| BPC-157 | ★★☆☆☆ | Poorly characterised | Not approved | Schedule 4 + Appendix D, clause 5 |
| CJC-1295 (with DAC) | ★★☆☆☆ | Poorly characterised | Not approved | Appendix D, clause 5 |
| Copper Peptide Hair Complex | ★★☆☆☆ | Poorly characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| EGF | ★★☆☆☆ | Poorly characterised | Cosmetic status varies | Schedule 7 (Dangerous Poison), except in preparations for human therapeutic use; Appendix G and Appendix J controls |
| GHRP-2 | ★★☆☆☆ | Poorly characterised | Not approved | Schedule 4 + Appendix D cl.5 (listed as Pralmorelin) |
| GHRP-6 | ★★☆☆☆ | Poorly characterised | Not approved | Schedule 4 + Appendix D cl.5 (named individually) |
| Glutathione | ★★☆☆☆ | Moderately characterised | Oral supplement lawful; injectable compounded, not FDA-approved | Oral supplement lawful; injectable Schedule 4 |
| Hexarelin | ★★☆☆☆ | Poorly characterised | Not approved | Schedule 4 + Appendix D cl.5 (named individually) |
| Ipamorelin | ★★☆☆☆ | Poorly characterised | Not approved | Schedule 4 + Appendix D, clause 5 |
| MK-677 | ★★★☆☆ | Moderately characterised | Not approved | Schedule 4 + Appendix D, clause 5 |
| Mod GRF (1-29) | ★★☆☆☆ | Poorly characterised | Not approved | Schedule 4; captured by Appendix D cl.5 class entry (GHRHs) |
| Noopept | ★★☆☆☆ | Poorly characterised | Not approved; not a lawful dietary supplement ingredient | Schedule 4 |
| Selank | ★★☆☆☆ | Poorly characterised | Not approved | Not listed by name; unapproved therapeutic good |
| Semax | ★★☆☆☆ | Poorly characterised | Not approved | Not listed by name; unapproved therapeutic good |
| TB-500 | ★★☆☆☆ | Poorly characterised | Not approved | Appendix D, clause 5 |
| Thymosin Beta-4 | ★★☆☆☆ | Poorly characterised | Not approved | Appendix D cl.5: possession without authority illegal (named individually) |
| VIP | ★★☆☆☆ | Poorly characterised | Investigational (aviptadil) | Schedule 4 |
| Zinc Thymulin | ★★☆☆☆ | Poorly characterised | Not approved | Not listed by name; unapproved therapeutic good |
Band 4: Insufficient data (39 peptides)
| Peptide | Evidence | Safety data | United States | Australia |
|---|---|---|---|---|
| 5-Amino-1MQ | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Adipotide | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| BPC-157 Arginate | ★☆☆☆☆ | Largely unknown | Not approved | Related to BPC-157, Appendix D cl.5 |
| Bremelanotide Analogues | ★★☆☆☆ | Poorly characterised | Varies; most not approved | Varies by compound; most unapproved |
| Carnosine | ★★★☆☆ | Well characterised | Dietary supplement: lawfully sold | Supplement: lawfully sold |
| CJC-1295 / Ipamorelin Blend | ★☆☆☆☆ | Largely unknown | Neither component approved | Both components S4 + Appendix D cl.5: possession without authority illegal |
| Cortagen | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Decorinyl | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Dihexa | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| DSIP | ★☆☆☆☆ | Largely unknown | Not approved; reviewed by PCAC July 2026 as Emideltide, outcome not published by FDA | Not listed by name; unapproved therapeutic good |
| Epitalon | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Eyeseryl | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Follistatin-344 | ★☆☆☆☆ | Largely unknown | Not approved | Appendix D cl.5: possession without authority illegal (named individually) |
| FOXO4-DRI | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Hepcidin | ★★☆☆☆ | Poorly characterised | Not approved | Not listed by name; unapproved therapeutic good |
| Hexapeptide-11 | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| hGH Fragment 176-191 | ★☆☆☆☆ | Largely unknown | Not approved | Schedule 4; related to AOD-9604 which is named in Appendix D cl.5 |
| Humanin | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| IGF-1 DES | ★☆☆☆☆ | Largely unknown | Not approved | Schedule 4 + Appendix D cl.5 (insulin-like growth factors, class entry) |
| IGF-1 LR3 | ★☆☆☆☆ | Largely unknown | Not approved | Schedule 4 + Appendix D cl.5 (insulin-like growth factors, class entry) |
| KPV | ★☆☆☆☆ | Largely unknown | Not approved; PCAC recommended Jul 2026 (8-6, one abstention) | Not listed by name; unapproved therapeutic good |
| Leuphasyl | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Livagen | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| LL-37 | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Matrixyl 3000 | ★★★☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Melanotan II | ★☆☆☆☆ | Poorly characterised | Not approved | Schedule 4 (Prescription Only) |
| MOTS-c | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| N-Acetyl Selank Amidate | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| N-Acetyl Semax Amidate | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| P21 | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Pinealon | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Progeline | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| SNAP-8 | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Syn-Ake | ★★☆☆☆ | Well characterised | Cosmetic ingredient: lawfully sold | Cosmetic ingredient: lawfully sold |
| Thymagen | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Thymalin | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Thymosin Beta-4 Fragments | ★☆☆☆☆ | Largely unknown | Not approved | Thymosin Beta 4 named in Appendix D cl.5 |
| Thymulin | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
| Vilon | ★☆☆☆☆ | Largely unknown | Not approved | Not listed by name; unapproved therapeutic good |
Why there is no number column
For Band 1 the number belongs to the label, and the label is specific to an indication, a formulation and a patient group that a chart cannot carry. For Band 2 it belongs to a trial, with its supervision and monitoring. For Band 3 there is no authority behind the figure at all, only repetition. For Band 4 there is nothing.
Each entry carries its own dosing section with the band stated and the source named. That is where a number can be read with the context that makes it mean anything.
Educational reference, not medical advice, and not a recommendation to use any compound. Dosing decisions belong with a qualified clinician who knows the person in front of them.